Nasdaq · Biotech stocks database
VRAX — Virax Biolabs Group Limited
VRAX (Virax Biolabs Group Limited) stock: $2.54, $3.4M market cap, $6.4M cash, -$2.7M EV, $1.5M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Balance sheet
| Cash | $6.4M |
|---|
| Debt | $0.3M |
|---|
| Net cash | $6.1M |
|---|
| Enterprise value | -$2.7M |
|---|
| Basic shares | 1.3M shares |
|---|
| Fully diluted shares | 0.6M shares |
|---|
| Fully diluted market cap | $1.5M |
|---|
| Cash per share | $4.81 |
|---|
Cash figures as of 2026-03-31. Database snapshot: 2026-09-21.
Price history
Loading VRAX daily closes…
Loading price history…
Asset data not yet available for this company.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.